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Screening and treatment for chronic hepatitis C are very limited in Vietnam and clinical data
on HCV-related liver disease in HIV-coinfected people are almost inexistent. This study
aimed to assess the severity of liver fibrosis and its risk factors in HIV-HCV coinfected
patients in Haiphong, Northern Vietnam.
Methods
A cross-sectional study was conducted at a HIV outpatient clinic. Consecutive HIV treated
adults with positive HCV serology completed a standardised epidemiological questionnaire
and had a comprehensive liver assessment including hepatic elastography (Fibroscan1,
Echosens).
Results
From February to March 2014, 104 HIV-HCV coinfected patients receiving antiretroviral
therapy (ART) were prospectively enrolled (99 males, median age: 35.8 (32.7–39.6) years,
median CD4 count: 504 (361–624) /mm3. Of them, 93 (89.4%) had detectable HCV RNA
(median 6.19 (4.95–6.83 Log10 IU/mL). Patients were mainly infected with genotypes 1a/1b
(69%) and genotypes 6a/6e (26%). Forty-three patients (41.3%) had fibrosisF2 including
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24 patients (23.1%) with extensive fibrosis (F3) and/or cirrhosis (F4). In univariate analysis,
excessive alcohol consumption, estimated time duration from HCV infection, nevirapine
and lopinavir-based ARV regimen and CD4 nadir were associated factors of extensive fibro-
sis/cirrhosis. Alcohol abuse was the only independent factor of extensive fibrosis in multi-
variate analysis. Using Fibroscan1 as a gold standard, the high thresholds of AST-to-
platelet ratio index (APRI) and fibrosis-4 score (FIB-4) had very good performances for the
diagnosis of extensive fibrosis/cirrhosis (Se: 90 and 100%, Sp:84 and 81%, AUROCs =
0.93, 95%CI: 0.86–0.99 and 0.96 (0.92–0.99), respectively).
Conclusion
In this study, nearly 25% of HIV-HCV coinfected patients successfully treated with ART
have extensive fibrosis or cirrhosis, and therefore require urgently HCV treatment.
Introduction
Over the last decade, access to HIV/AIDS care and antiretroviral therapy (ART) has been
greatly improved in resource-limited countries and the number of AIDS-related deaths is now
steadily decreasing [1]. Hepatitis C virus (HCV) infection, which is a major public health prob-
lem globally [2] is frequently observed in HIV-infected individuals and has emerged as a lead-
ing cause of morbidity and mortality in this population [3].
In Vietnam, HCV seroprevalence has been reported between 1 to 6% of the general popula-
tion [4] and is dramatically higher (up to 90%) in people who inject drug (PWID) [4–10]. The
HIV epidemic is concentrated among high risk populations, such as female sex workers (preva-
lence 2.6%), men who have sex with men (3.7%) and PWID (10.3%) [11]. Despite huge efforts
to control the national HIV epidemic among PWID by scaling up ART, needle & syringe
exchange programmes and opioid substitution treatment, PWID still represent the vast major-
ity of people living with HIV/AIDS in Vietnam with a high rate of HCV coinfection.
The Vietnamese Ministry of Health has recently developed national HCV Guidelines upon
the release of the first World Health Organization (WHO) Guidelines on HCV care and treat-
ment [2]. However screening and access to care and treatment for chronic hepatitis C in Viet-
nam are still very limited. To date, no clinical data on HCV-related liver disease are available in
people living with HIV/AIDS in Vietnam and therefore the proportion of patients in need of
treatment is unknown. Since new highly effective direct antiviral agents DAAs will soon be rec-
ommended by WHO as preferred options for treatment globally and are increasingly recom-
mended by national guidelines and some of them have now become available at generic price,
access to these drugs in resource-constrained areas has been urged by the medical community
and the civil society [12–15].
Therefore, it is critical to identify patients in need of urgent treatment in developing coun-
tries, which bear the highest burden of HCV-related liver disease.
The following cross-sectional study aimed to assess the proportion of clinically significant
fibrosis (F2) in HIV-HCV-coinfected patients followed in Viet Tiep Hospital in Haiphong,
Northern Vietnam. We also identified epidemiological, virological and clinical characteristics
associated with extensive fibrosis/cirrhosis. Since WHO [2] ranked the aspartate transaminase
(AST)-to-platelet ratio index (APRI) and Fibrosis-4 score (FIB-4) as preferred non-invasive
markers of fibrosis in resource-limited settings, we also evaluated the diagnostic performances
of these tests in our HIV-HCV coinfected population using hepatic transient elastography
(Fibroscan1) as a gold standard.
HIV-HCV Coinfection in Vietnam
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Patients and Methods
Study population
Among the 1,184 HIV-infected patients (including 1,173 (99%) under ART) who are regularly
followed up in the outpatient clinic (OPC) of Viet Tiep hospital in Haiphong, we prospectively
enrolled consecutive HIV-infected patients under ART with a HCV positive rapid test (SD Bio-
line anti-HCV rapid test (Standard Diagnostics Inc., Korea), who visited the clinic for their reg-
ular HIV follow-up between February and March 2014. As the ultimate goal of this study was
to identify and characterize patients who may benefit from HCV treatment (only peg-inter-
feron and ribavirine have been registered as HCV antiviral therapy in Vietnam), eligibility cri-
teria for this cross-sectional study were: being over 18 years old, HCV treatment-naïve, under
ART for more than 6 months with CD4 200/mm3 and having no contra-indications to
immediate interferon-based HCV treatment i.e: ongoing opportunistic infection, concomitant
malignancy, severe anemia defined by Hb<8 g/dL, decompensated cirrhosis, acute heart fail-
ure, severe psychiatric disorders, pregnancy, platelet count<50,000/mm3, neutrophil count
<750/mL measured in the past 6 months. Only participants with a confirmed positive HCV
serology were included in the final analysis.
The study, its protocol and the written consent procedure were approved by the Ethic Com-
mittee of the Viet Tiep Hospital and the Institutional Review Board (IRB) of the Haiphong
Medical Services (permit number 01BVVT/HDKH). Before enrollment in the following study,
all participants provided written consents which have been kept at the ANRS site in Vietnam
as recommended by the IRB. The study was carried out in strict accordance with the recom-
mendations of the Haiphong healthcare services and the Helsinki declaration.
Clinical assessment
Each participant was administrated a face-to-face standardized socio-demographic question-
naire in Vietnamese, had a clinical examination and a comprehensive liver assessment by a
trained medical doctor. Heavy alcohol consumption was defined as a daily consumption over
50 g per day. HCV duration was estimated as “time from HCV diagnosis” defined by the dura-
tion between the discovery of HCV infection (defined by positive HCV antibody) and the time
of enrolment in our study.
Liver fibrosis was assessed using transient elastography (Fibroscan 402, Echosens, France)
by two trained experienced operators (TNT, DL) according to the manufacturer’s protocol
[16]. The value of liver stiffness measurement (LSM) was expressed in kilopascal (kPa) as the
median of 10 successful acquisitions. Unreliable measurement was defined as interquartile
range (IQR)/LSM of>0.30 when LSM is7.1 kPa according to Boursier et al. criteria [17].
LSM were all done fasting as recommended [18, 19]. The following cut-offs were used to stage
the liver fibrosis: fibrosis F0-F1<7.1 kPa; F2: 7.1–9.4 kPa; F3: 9.5–12.4 kPa, F4> 12.4 kPa [20].
Laboratory investigations
The following blood parameters were determined after overnight fasting in the laboratory of
Viet Tiep hospital on the same day as transient elastography in all patients: AST, alanine ami-
notransferase (ALT), gamma-glutamyltransferase (GGT), total bilirubin, platelet count, serum
albumin and prothrombin time. All participants had a confirmatory test for HCV serology by
Enzyme-linked Immunosorbent essay (ELISA) technique using Phamatech anti HCV EIA kit
(USA). The plasma was prepared and stored at -20°C in Viet Tiep Hospital then transferred to
Pasteur Institute in Ho Chi Minh City for HIV and HCV RNA quantification and HCV geno-
typing. HIV and HCV RNA were extracted from plasma samples using MagNa Pure 96 system
HIV-HCV Coinfection in Vietnam
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kit on the LightCycler1 480 instrument (Roche, USA). HIV viral load was measured by HIV
RNA levels (Generic HIV Viral Load1, Biocentric, France) with a detection limit of 300 cop-
ies/mL [21]. HCV RNA was quantified by HCV Real-time Quant kit (Sacace Biotechnologies,
Italy) with a detection limit of 15 IU/mL.
HCV genotyping was performed for samples with HCV RNA level above 1,000 copies/mL.
An in-house assay was applied in which a targeting of 377 bp HCV NS5b region or 464 bp core
gene was amplified by ABI 9700 PCR instrument and sequenced by CEQ 8000 Genetic Analy-
sis System (Beckman Coulter). HCV subtypes were identified using the Los Alamos Hepatitis
C sequence (www.hcv.lanl.gov).
Statistical analysis
All data were registered anonymously in a computerized database. The description of socio-
demographical, clinical, biochemical, hematological, virological and immunological parameters
was performed using standard descriptive methods, i.e. categorical variables were expressed as
raw numbers and percentages, continuous variables were described by their means and standard
deviation (normal distribution) or their median and IQR 25–75% (non normal distribution
assessed by Shapiro-Wilks test). The proportion of F3-F4 fibrosis was assessed as the number of
patients with LSM above 9.4kPa and expressed with its 95% confidence interval. Mean (+/- stan-
dard derivation (SD)) score was also determined and used as a continuous variable. As transient
elastography has been shown to predict portal hypertension in chronic liver disease [22] and
LSM values above 20 and 40 kPa have been proved to be associated with a high risk of portal
hypertension and cirrhosis-related complications, respectively [20], we also reported the number
of patients with LSM>20 kPa and>40 kPa. Categorical variables were compared using a Pear-
son v2-test or Fisher’s Exact Test as appropriate, and continuous variables were compared using
a Student’s t test or non-parametric tests as appropriate. A two-sided P value<0.05 was consid-
ered statistically significant. The diagnostic performances of APRI and FIB-4 in diagnosing
advanced fibrosis(F3)/cirrhosis were evaluated from the Area Under the ROC curves (AUROCs),
considering transient elastography as the gold standard. Two thresholds for fibrosis F4 with
APRI were examined: 2 (high threshold) and 1 (low threshold), as per WHO hepatitis C Guide-
lines [2]. Likewise, two thresholds for fibrosis F3 with FIB-4 were examined: 3.25 (high thresh-
old) and 1.25 (low threshold). The degree of correlation between both biochemical scores and
result of elastometry was also explored using Spearman correlation test. Finally, risk factors for
liver fibrosisF3 were assessed by means of two methods: i) outcome expressed as a dichoto-
mous variable (< or F2): univariate and multivariate logistic regression with odds ratios (OR)
and 95% confidence intervals; ii) outcome expressed as a continuous variable (LSM): univariate
and multivariate linear regression with β parameters and 95% confidence intervals (CI). Statisti-
cal analyses were performed using STATA 11 statistical package for Windows.
Results
Study population
Out of the 1,184 HIV patients who are regularly followed up in the OPC of the Viet Tiep hospi-
tal, 1,158 (97.8%) had a systematic screening for HBs antigen and HCV antibody and 390
(33.7%) had a positive HCV test. Of the 390 patients tested positive for HCV antibody, 200
(51.3%) were eligible for the following study. Of these 200 patients, 111 consecutive HIV and
HCV co-infected adults were enrolled from February to March 2014 (Fig 1).
However, seven had a negative HCV confirmatory serological test and were excluded from
further assessment. Therefore, the study population consisted of 104 patients, whose demo-
graphic, clinical and biological characteristics are summarized in Tables 1 and 2.
HIV-HCV Coinfection in Vietnam
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Study participants were mainly men (95.2%) with a median age of 35.8 (32.7–39.6) years. At
enrolment, they were all under ART (most prescribed 3rd agent: efavirenz with a backbone of
TDF/3TC or D4T/3TC or AZT/3TC), with 94.2% rate of undetectable HIV-RNA and a median
CD4 cell count of 504 (361–624) /mm3. The median duration from HIV diagnosis was 6.3
(3.1–7.8) years.
Of the 104 study participants, 72 (69.2%) reported past injection drug use while 24 (33%)
were still injecting drugs and 21 (20.2%) were receiving opiate substitution treatment. Current
or past excessive alcohol consumption was reported in 70 (67.3%) patients. The prevalence of
positive HBs antigen (HBsAg) was 12.6% (95% CI: 10.4–14.8). All of the 13 HBV-infected
patients except one had undetectable HBV DNA.
Hepatitis C and liver fibrosis evaluation. Among the 104 patients with confirmed HCV
antibodies, 93 (89.4%) had a positive HCV RNA with a median viral load of 6.19 (4.95–6.83
Log10 IU/mL). Genotype distribution showed a highest proportion of genotypes 1 (64 (68.8%),
genotype 1a and 1b: 42 (45.2%) and 22 (23.7%), respectively),followed by genotype 6 (24 (25.8%),
genotype 6a and 6b: 19 (20.4%) and 5 (5.4%), respectively) and genotype 3b (5 (5.4%)). A valid
LSMwas obtained for all the subjects: median LSM 6.7 kPa (5.3–9.2). According to the predeter-
mined cut-offs for liver fibrosis, 61 (68.7%) patients were classified as having no or mild fibrosis
(F1),19 (18.3%) as having clinically significant fibrosis (F2), 10 (9.6%) as having extensive fibrosis
(F3) and 14 (13.5%) as having cirrhosis (F4). All cirrhotic subjects had compensated liver disease
and 2 were classified Child-Pugh score B. Of the 14 cirrhotic patients, 8 (57%) had LSM over 20
kPa suggesting clinically significant portal hypertension and 2 (14%) had LSM over 40 kPa, a cut-
off associated with high risk of cirrhosis-related complications.
Fig 1. Flowchart of the study population.
doi:10.1371/journal.pone.0153744.g001
HIV-HCV Coinfection in Vietnam
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Patients with extensive fibrosis/cirrhosis had lower platelet count (P = 0.003) and lower pro-
thrombin time (p<0.0001), and higher ALT, AST, GGT and total bilirubin levels, (P<0.0001)
compared to patients with none to moderate fibrosis. A higher rate of alcohol consumption
and a trend towards longer time from HCV diagnosis were also noted in patients with severe
fibrosis (83.3% versus 62.5% P = 0.04 and 9 years versus 4.6 years P = 0.08, respectively). The
proportion of patients with severe fibrosis was similar across HCV genotype (Table 2).
Risk factors for advanced fibrosis/cirrhosis. In univariate analysis with fibrosis as a
dichotomous variable (F0-F2 versus F3-F4), the following factors were associated with exten-
sive fibrosis/cirrhosis: current or past excessive alcohol consumption, HCV time from diagno-
sis, nevirapine or lopinavir-based ART regimen and CD4 nadir. After adjustment, the only
factor remaining associated with F3-F4 score was current or past excessive alcohol consump-
tion (OR: 4.2, 95% CI: 1.1–15.4). In multivariate analysis with transient elastography as a con-
tinuous variable, heavy alcohol consumption remained strongly associated with high LSM
values (β = 36.04 (3.95–68.13), p<0.03)
Performance of APRI and FIB-4 scores for the diagnosis of advanced fibrosis/cirrho-
sis. The correlation between APRI and elastography scores was good (rho = 0,49, P<0,0001)
and very good for FIB-4 and elastography (rho = 0,72, P<0,0001). For the diagnosis of
advanced fibrosis/cirrhosis, the performance of APRI (high threshold at 2) was very good (Fig
2A and Table 3) with an AUROC at 0.93 (95% IC, 0.86–0.99) and 87 (84%) of the patients
were correctly classified. Using the low APRI threshold at 1, AUROC was only 0.75 (95% IC,
Table 1. Description of the study population according to the liver fibrosis status. Continuous variables are expressed with their median and interquar-
tile range (IQR) for the general population and mean and standard deviation (SD) when categorized by liver fibrosis group.
General population
n = 104
Patients with F0-2 liver
ﬁbrosis n = 80
Patients with F3-4 liver




Male gender (n, %) 99 (95.2) 75 (93.8) 24 (100) 0.6
Age, years 35.8 (32.7–39.6) 37.1 (6.2) 36.6 (5.5) 0.9
BMI, kg/m2 19.6 (18.4–21.6) 20.1 (2.0) 20.1 (2.3) 0.8
IV drug use as way of HCV transmission (n, %) 72 (69.2) 56 (70) 16 (66.7) 0.8
Current or past excessive alcohol consumption
(n, %)
70 (67.3) 50 (62.5) 20 (83.3) 0.04
Current tobacco use (n, %) 82 (78.9) 65 (81.3) 17 (70.8) 0.3
Current cannabis use (n, %) 16 (15.4) 11 (13.8) 5 (20.8) 0.5
Current use of any drugs (including injecting) (n,
%)
8 (10.8) 6 (10.3) 2 (12.5) 0.9
Current use of injecting drugs (n, %) 9 (12.7) 7 (12.5) 2 (13.3) 0.9
Current oral opioid substitution (n, %) 21 (20.2) 18 (22.5) 3 (12.5) 0.4
HIV characteristics
Estimated duration of HIV infection from ﬁrst
screening, years
6.3 (3.1–7.8) 6.6 (4.0) 5.7 (3.8) 0.4
CD4 nadir, per mm3 84 (38–175) 113 (113.4) 133 (110.2) 0.2
Current CD4 count, per mm3 504 (361–624) 521 (210.2) 471 (159.6) 0.4
Undetectable HIV-RNA (n, %) 98 (94.2) 75 (93.8) 23 (95.8) 0.9
Duration of cART, years 4.3 (4.1–6.0) 4.2 (1.9) 3.8 (1.9) 0.3
Type of ART
2 NNRTI and Nevirapine 7 (6.7) 4 (5) 3 (12.5) 0.07
2 NNRTI and Efavirenz- 91 (87.5) 73 (91.3) 18 (75.0) 0.08
2 NNRTI and Lopinavir/ritonavir 6 (5.8) 3 (3.5) 3 (12.5) 0.07
HBsAg positivity (n, %), n = 103 13 (12.6) 9 (11.3) 4 (12.6) 0.5
doi:10.1371/journal.pone.0153744.t001
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0.64–0.86) (Fig 2B and less patients (78, 75%) were correctly classified. Using the high cut-off
APRI score allowed maximising the sensitivity of the score (90%) while keeping the same level
of specificity (84%) (Table 3). The same calculations were applied to FIB-4: for the diagnosis of
advanced fibrosis (F3), the performance of FIB-4 (high threshold at 3.25) was very good (Fig
3A and Table 3) with an AUROC at 0.96 (95% IC, 0.92–0.99) and 85 (82%) of the patients
were correctly classified. Using the low FIB-4 threshold at 1.25, AUROC was only 0.76 (95% IC
0.64–0.88) (Fig 3B) and less patients (82.79%) were correctly classified (Table 3)
Discussion
Our study suggests that among HIV-HCV coinfected subjects under ART who are attending
the outpatient clinic in Haiphong, Northern Vietnam, almost half of them have clinically sig-
nificant fibrosis (F2) including one fourth with extensive fibrosis or cirrhosis despite optimal
HIV viro-immunological control. We confirm that genotypes 1 and 6 are the predominant
Table 2. Hepatitis C characteristics of the study population according to the liver fibrosis status Continuous variables are expressed with their
median and interquartile range (IQR) for the general population andmean and standard deviation (SD) when categorized by liver fibrosis group.
General population
n = 104
Patients with F0-2 liver ﬁbrosis
n = 80
Patients with F3-4 liver ﬁbrosis
n = 24
P value
Estimated time from HCV diagnosis,
years
4.8 (2.7–6.5) 4.6 (2.1) 9.0 (22.4) 0.08
Detectable HCV-RNA, n (%) 93 (89.4) 70 (87.5) 23 (95.8) 0.5
HCV-RNA, Log10 6.19 (4.95–6.83) 5.93 (1.26) 5.91 (0.99) 0.7
HCV genotype 1 64 (68.8) 49 (70.0) 15 (65.2) 0.9
HCV genotype 3b 5 (5.4) 4 (5.7) 1 (4.4) 0.8
HCV Genotype 6 24 (25.8) 17 (24.3) 7 (30.4) 0.6
Platelets, 109/L 214 (177–267) 235 (71) 189 (86) 0.003
ALT, IU/mL 62 (40–95) 62 (34) 128 (92) 0.0001
AST, IU/mL 48 (38–68) 47 (20) 105 (58) 0.0001
GGT, IU/mL 143 (93–378) 23.5 (210.5) 67.9 (332.5) 0.0001
Total Bilirubin mg/dL 10 (7–13.5) 9.9 (4.3) 16.3 (9.2) 0.0001
Albumin, g/L 43 (41–45) 41.8 (7,0) 41.0 (8.7) 0.9
Prothrombin time, % 91 (79–99) 93 (22) 79 (17) 0.002
LSM, kPa 6.7 (5.3–9.2) 6.1 (1.5) 18.4 (11.6) 0.0001
APRI score 0.7 (0.4–1.4) 0.7 (0.5) 2.2 (1.9) 0.0001
FIB-4 score 1.09 (0.78–1.58) 1.01 (0.77–1.25) 1.92 (1.28–1.83) <0.0001
doi:10.1371/journal.pone.0153744.t002
Fig 2. Performance of APRI in diagnosing extensive fibrosis (F3) and cirrhosis using a high threshold
(APRI > 2) (Fig 1A) and a low threshold (APRI>1) (Fig 1B).
doi:10.1371/journal.pone.0153744.g002
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HCV genotypes circulating among this group but in different proportions than in Hai Phong
and other regions of Vietnam.
Few studies on HCV infection have been conducted in Vietnam. These studies were mainly
sero-epidemiological surveys without clinical evaluation of the liver disease [9, 23, 24]. In
Southeast Asia, only one study from Thailand assessed the degree of liver fibrosis in 130
HIV-HCV co-infected individuals [25]. This study reported 41.7% of HIV-HCV coinfected
patients with extensive fibrosis F3/F4 using Fibroscan1. Out of them 24% were classified as cir-
rhotics. Cross-sectional studies conducted in Western countries also reported high proportions
of extensive fibrosis and cirrhosis in cohorts of HCV naïve of treatment HIV-HCV coinfected
subjects [26–29]. The higher rates of extensive fibrosis observed in the Thai and Western stud-
ies compared to our results may be explained by the differences in age (our patients were much
younger) and estimated time from HCV infection. The median duration of HCV exposure was
over 17 years in the Thai study and the Western studies as compared to an estimated median
HCV contamination below seven years in our study.
Interestingly, the short period from HCV diagnosis (4.8 (2.7–6.5) years) suggests that HCV
infection was long neglected in Vietnam, as systematic HCV screening has been implemented
only in 2005 in HIV clinics.
Haiphong city experiences important rates of injection drug use in young individuals [30].
Indeed, it is a well-established area within the “Golden Triangle” for heroin supply at low price
and has become an attractive area for PWID [30]. In our study, as expected the use of injecting
drugs was frequently associated with HCV infection among HIV positive patients and HCV
transmission was attributable to the use of intravenous drug in almost two third of the cases.
This is in line with other studies from Vietnam, and other Asian countries that reported a high
prevalence of HCV infection, up to 96% in injecting drug users [9, 10, 31]. In Hanoi, among
HIV-infected individuals, 35.4% were tested positive for HCV and HIV-HCV coinfection was
mainly observed in young males. In this study, the use of injecting drug was reported as a trans-
mission factor in 44% of cases [23].
Table 3. Performances of APRI and FIB-4 in predicting advanced fibrosis /cirrhosis (F3/F4) using transient elastography as a gold standard.
Abbreviations: AUROC: area under the receiving operator curve; Se: sensitivity; Sp: specificity; LR-: negative likelihood ratio; LR+: positive likelihood ratio.
AUROC (95%CI) Se (%) Sp (%) Correctly classiﬁed, (%) LR- LR+
High APRI threshold (2) 0.93 (0.86–0.99) 90 84 84.6 0.11 7.69
Low APRI threshold (1) 0.75 (0.64–0.86) 47 90 75 0.59 4.59
High FIB-4 threshold (3.25) 0.96 (0.92–0.99) 100 81 81.9 0 5.96
Low FIB-4 threshold (1.25) 0.76 (0.64–0.88) 53 88 77.9 0.53 4.39
doi:10.1371/journal.pone.0153744.t003
Fig 3. Performance of FIB-4 in diagnosing extensive fibrosis (F3) using a high threshold (FIB-4 > 3.25)
(Fig 3A) and a low threshold (FIB-4 > 1.25) (Fig 3B).
doi:10.1371/journal.pone.0153744.g003
HIV-HCV Coinfection in Vietnam
PLOSONE | DOI:10.1371/journal.pone.0153744 May 5, 2016 8 / 13
As suggested by previous studies, we confirm that genotypes 1 and 6 are the most frequent
circulating genotypes in Vietnam [32, 33]. However, genotype 6 was not the predominant cir-
culating genotype in our study population although previous studies reported a higher preva-
lence of HCV genotype 6 in Vietnam [32, 33].
While Avihingsanon et al. observed a lower rate of severe fibrosis in HCV genotype 6-infected
subjects in Thailand, we did not find any difference in fibrosis stage according to genotype.
We assessed the severity of liver fibrosis using Fibroscan1 as its excellent performances
have been demonstrated in HCV-infected as well as HIV-HCV co-infected individuals [20, 34,
35]. In addition, liver biopsy is not feasible in routine clinical practice in resource-limited coun-
tries. However, the Fibroscan1 device is rarely available in these countries mainly because of
its high cost (€34,000 for the portable machine and €5,000 for the annual maintenance cost). In
Vietnam only a few machines are available in the country and are mainly accessible in the pri-
vate sector. As a result the WHO recommends the use of APRI or FIB-4 as simple and inexpen-
sive alternative methods to identify patients with extensive fibrosis and cirrhosis in resource-
constrained countries [2]. Using Fibroscan1 as a gold standard, we found that APRI and FIB-4
performed very well in diagnosing extensive fibrosis/cirrhosis (AUROC>0.90) when using the
high thresholds of 2 for APRI and 3.25 for FIB-4.
Since international guidelines recommend to prioritize treatment in patients with extensive
fibrosis or cirrhosis [36], we focused our analysis on F3-F4 patients. A recent model-based
analysis performed in resource-limited countries (Egypt, Thailand, Côte d’Ivoire) also sug-
gested that focusing HCV treatment on patients with severe fibrosis (F3–F4) using standard of
care therapy (Peg-interferon and ribavirin) or interferon-free therapy (sofosbuvir and ribavi-
rin), is the best strategy for developing countries as it provides the highest number of life per
year saved [37]. Several studies have also shown that HCV antiviral therapy in IDUs, especially
in those on opioid substitution treatment, is associated to identical sustained virological
response compared to non-or former IDUs [38, 39]. In addition, there is an increase evidence
to propose HCV therapy as a cost-effective intervention to reduce the burden of HCV infection
and transmission in this specific population [40, 41].
Our study clearly suggests that a high proportion of IDUs in Vietnam urgently requires
HCV antiviral therapy. Based on our analysis and considering that there is 200,000 IDUs in
Vietnam, about 150,000 of them (70%) have been infected with HCV, 80% of them (120,000)
have a chronic HCV hepatitis and at least 30,000 could be pre-cirrhotic or cirrhotic with a risk
of hepatic decompensation or HCC over the next years if they do not benefit of antiviral treat-
ment soon.
Interestingly, almost all our study participants (95%) had a good HIV viro-immunological
control. This reflects the great efforts that have been deployed over the last decades in Vietnam
to fight against HIV/AIDS and expand ART also to the most stigmatized populations. Thus, if
access to HCV treatment is not improved, the benefits of ART on mortality will be clearly
undermined.
In our study, heavy alcohol consumption was the only statistical difference between patients
with extensive fibrosis or cirrhosis and those with none to moderate fibrosis. It was also a
strong independent factor of severe fibrosis. By contrast with other studies, age, estimated
duration of HIV or HCV infection and ARV regimen were not statistically associated with
extensive liver fibrosis/cirrhosis although a trend was noted for the HCV duration. This under-
lines that excessive alcohol consumption is an important contributor of liver fibrosis progres-
sion in this population. Heavy alcohol consumption has been previously reported as a major
public health problem in Vietnam in particular in men [4, 42]. Unfortunately, alcohol is
another neglected problem in many resource-limited countries and must be clearly integrated
in harm reduction programmes [2].
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Our study has some limitations. First, it is a cross-sectional study including a small number
of patients, with a reduced statistical power to assess risk factors, which may not strictly reflect
the burden of HCV-related burden disease in HIV-HCV individuals in Vietnam. Secondly,
since the most severe cases have been seen mainly in inpatient clinic, our study may have
underestimated the proportion of patients with end-stage liver disease. Thirdly, we assessed the
diagnostic performances of biochemical markers of fibrosis using transient elastography as a
gold standard although we could not validate its performances against liver biopsy in our study
population. However, excellent performances of Fibroscan in predicting liver fibrosis in Asian
HCV subjects have been previously reported using liver histology as a gold standard [43].
Finally, we could not properly assess the proportion of patients with liver complications (in
particular portal hypertension) due to resource-limited constraints.
Our findings underline the urgent need of HCV “screen and treat” intervention pro-
grammes in Vietnam. Among HIV-HCV coinfected subjects successfully treated with ART,
our study suggests that about 25% of patients urgently require HCV antiviral therapy. This
underlines the necessity to rapidly expand access to HCV treatments adapted to the local epi-
demiology (genotypes 1 & 6). This will comply with the recent WHO recommendations [2]
and its urgent call to deploy strategies to reduce the burden of viral hepatitis especially in
endemic resource-constrained areas [44] and eventually eliminate the epidemic globally [45].
Acknowledgments
We would like to thank all the participants, Prof. Hoang Van Mich (director of Viet Tiep Hos-
pital), the entire team of the HIV outpatient clinic and Dr Catherine Quillet for supporting the
data management of the study. We are really grateful to Echosens France, in particular Jean-
Marc David and Céline Fournier, for offering the Fibroscan1machine. We also thank the
French national research agency on HIV and viral hepatitis (ANRS) and its director Prof. Jean-
François Delfraissy. Finally we want to acknowledge Prof. Françoise Barre-Sinoussi, the French
coordinator of the ANRS Vietnam site, for her strong support.
Author Contributions
Conceived and designed the experiments: ML DL TNT KL SD HDT LTTX. Analyzed the data:
KL ML ET TNT DL. Contributed reagents/materials/analysis tools: ML TNT DL KL HDT
PPTH LTTX NCT ALQ VVH NN ET SD. Wrote the paper: ML KL DL TNT NN ET. Contrib-
uted to the study and approved the final version of the manuscript: ML TNT DL KL HDT
PPTH LTTX NCT ALQ VVH NN ET SD.
References
1. UNAIDS. http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/
gr2013/UNAIDS_Global_Report_2013_en.pdf Last accessed 3rd of June 2014. 2013.
2. WHO;. Guidelines for the screening, care and treatment of persons with hepatitis C infection http://
whoint/hiv/pub/hepatitis/hepatitis-c-guidelines/en/ Accessed 18t March 2015. 2014.
3. Joshi D O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients
with HIV infection. Lancet. 2011; 377(9772):1198–209. PMID: 21459211. doi: 10.1016/S0140-6736
(10)62001-6
4. Gish RG, Bui TD, Nguyen CT, Nguyen DT, Tran HV, Tran DM, et al. Liver disease in Viet Nam: screen-
ing, surveillance, management and education: a 5-year plan and call to action. Journal of gastroenterol-
ogy and hepatology. 2012; 27(2):238–47. doi: 10.1111/j.1440-1746.2011.06974.x PMID: 22098550.
5. Viet nam HIV/AIDS ESTIMATES AND PROJECTIONS 2007–2012. MINISTRYOF HEALTH–VIET
NAM ADMINISTRATIONOF HIV/AIDS CONTROL.
HIV-HCV Coinfection in Vietnam
PLOSONE | DOI:10.1371/journal.pone.0153744 May 5, 2016 10 / 13
6. Kallman JB, Tran S, Arsalla A, Haddad D, Stepanova M, Fang Y, et al. Vietnamese community screen-
ing for hepatitis B virus and hepatitis C virus. Journal of viral hepatitis. 2011; 18(1):70–6. doi: 10.1111/j.
1365-2893.2010.01278.x PMID: 20196807.
7. Sereno L, Mesquita F, Kato M, Jacka D, Nguyen TT, Nguyen TN. Epidemiology, responses, and way
forward: the silent epidemic of viral hepatitis and HIV coinfection in Vietnam. J Int Assoc Physicians
AIDS Care (Chic). 2012; 11(5):311–20. Epub 2012/07/26. doi: 10.1177/1545109712453939 PMID:
22828983.
8. Clatts MC, Colón-López V, Giang LM, Goldsamt LA. Prevalence and Incidence of HCV Infection
among Vietnam Heroin Users with Recent Onset of Injection. Journal of Urban Health: Bulletin of the
New York Academy of Medicine 2009; 87(2). doi: 10.1007/s11524-009-9417-9
9. Quan VM, Go VF, Nam le V, Bergenstrom A, Thuoc NP, Zenilman J, et al. Risks for HIV, HBV, and
HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care.
2009; 21(1):7–16. PMID: 19085215. doi: 10.1080/09540120802017610
10. Zhang L, Celentano DD, Le Minh N, Latkin CA, Mehta SH, Frangakis C, et al. Prevalence and corre-
lates of HCVmonoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.
European journal of gastroenterology & hepatology. 2015; 27(5):550–6. doi: 10.1097/MEG.
0000000000000321 PMID: 25769097; PubMed Central PMCID: PMC4380662.
11. Vietnam AIDS response progress report 2014. National committee for AIDS, drugs and prostitution pre-
vention and control. Hanoi.
12. Ford N, Singh K, Cooke GS, Mills EJ, von Schoen-Angerer T, Kamarulzaman A, et al. Expanding
access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clinical infec-
tious diseases: an official publication of the Infectious Diseases Society of America. 2012; 54
(10):1465–72. Epub 2012/03/21. doi: cis227 [pii] doi: 10.1093/cid/cis227 PMID: 22431808.
13. Lemoine M, Thursz M. Hepatitis C, a global issue: access to care and new therapeutic and preventive
approaches in resource-constrained areas. Seminars in liver disease. 2014; 34(1):89–97. Epub 2014/
05/02. doi: 10.1055/s-0034-1371082 PMID: 24782262.
14. Jayasekera CR, Barry M, Roberts LR, Nguyen MH. Treating hepatitis C in lower-income countries. The
New England journal of medicine. 2014; 370(20):1869–71. doi: 10.1056/NEJMp1400160 PMID:
24720680.
15. Lemoine M, Thursz M, Njie R, Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited
settings, recall for action. Liver international: official journal of the International Association for the
Study of the Liver. 2014; 34(1):12–5. Epub 2013/09/04. doi: 10.1111/liv.12283 PMID: 23998284.
16. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new
noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12):1705–13.
Epub 2003/12/31. PMID: 14698338.
17. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliabil-
ity criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013; 57(3):1182–91.
doi: 10.1002/hep.25993 PMID: 22899556.
18. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, et al. Liver stiffness is influ-
enced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evo-
lution. Hepatology. 2013; 58(1):65–72. Epub 2013/03/01. doi: 10.1002/hep.26343 PMID: 23447459.
19. Lemoine M, Shimakawa Y, Njie R, Njai HF, Nayagam S, Khalil M, et al. Food intake increases liver stiff-
ness measurements and hampers reliable values in patients with chronic hepatitis B and healthy con-
trols: the PROLIFICA experience in The Gambia. Alimentary pharmacology & therapeutics. 2014; 39
(2):188–96. Epub 2013/12/07. doi: 10.1111/apt.12561 PMID: 24308698.
20. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of
transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepati-
tis C. Gastroenterology. 2005; 128(2):343–50. Epub 2005/02/03. PMID: 15685546.
21. Nacro B, Zoure E, Hien H, Tamboura H, Rouet F, Ouiminga A, et al. Pharmacology and immuno-viro-
logic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial. Bulletin
of theWorld Health Organization. 2011; 89(6):451–8. doi: 10.2471/BLT.10.081646 PMID: 21673861;
PubMed Central PMCID: PMC3099551.
22. Shi KQ, Fan YC, Pan ZZ, Lin XF, Liu WY, Chen YP, et al. Transient elastography: a meta-analysis of
diagnostic accuracy in evaluation of portal hypertension in chronic liver disease. Liver international: offi-
cial journal of the International Association for the Study of the Liver. 2013; 33(1):62–71. doi: 10.1111/
liv.12003 PMID: 22973991.
23. Huy BV, Vernavong K, Kinh NV. HBV and HCV Coinfection among HIV/AIDS Patients in the National
Hospital of Tropical Diseases, Vietnam. AIDS research and treatment. 2014; 2014:581021. doi: 10.
1155/2014/581021 PMID: 25580287; PubMed Central PMCID: PMC4274838.
HIV-HCV Coinfection in Vietnam
PLOSONE | DOI:10.1371/journal.pone.0153744 May 5, 2016 11 / 13
24. Ye S, Pang L, Wang X, Liu Z. Epidemiological implications of HIV-hepatitis C co-infection in South and
Southeast Asia. Current HIV/AIDS reports. 2014; 11(2):128–33. doi: 10.1007/s11904-014-0206-z
PMID: 24682917.
25. Avihingsanon A, Jitmitraparp S, Tangkijvanich P, Ramautarsing RA, Apornpong T, Jirajariyavej S, et al.
Advanced liver fibrosis by transient elastography, fibrosis 4, and alanine aminotransferase/platelet ratio
index among Asian hepatitis C with and without human immunodeficiency virus infection: role of vitamin
D levels. Journal of gastroenterology and hepatology. 2014; 29(9):1706–14. doi: 10.1111/jgh.12613
PMID: 24730732.
26. Carton JA, Collazos J, de la Fuente B, Garcia-Alcalde ML, Suarez-Zarracina T, Rodriguez-Guardado
A, et al. Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV.
Antiviral therapy. 2011; 16(1):27–35. doi: 10.3851/IMP1708 PMID: 21311106.
27. Kirk GD, Astemborski J, Mehta SH, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by
transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection.
Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;
48(7):963–72. PMID: 19236273.
28. Macias J, Recio E, Vispo E, Rivero A, Lopez-Cortes LF, Rios MJ, et al. Application of transient elasto-
metry to differentiate mild frommoderate to severe liver fibrosis in HIV/HCV co-infected patients. Jour-
nal of hepatology. 2008; 49(6):916–22. doi: 10.1016/j.jhep.2008.07.031 PMID: 18929426.
29. Cacoub P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, et al. Comparison of non-inva-
sive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study—ANRS HC02. Journal
of hepatology. 2008; 48(5):765–73. doi: 10.1016/j.jhep.2008.01.025 PMID: 18314219.
30. Ahmed T, Long TN, Huong PT, Stewart DE. Drug injecting and HIV risk among injecting drug users in
Hai Phong, Vietnam: a qualitative analysis. BMC public health. 2015; 15:32. doi: 10.1186/s12889-015-
1404-3 PMID: 25631330; PubMed Central PMCID: PMC4324409.
31. Solomon SS, Mehta SH, Srikrishnan AK, Solomon S, McFall AM, Laeyendecker O, et al. Burden of
hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a
cross-sectional study. The Lancet Infectious diseases. 2015; 15(1):36–45. doi: 10.1016/S1473-3099
(14)71045-X PMID: 25486851.
32. Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, Akkarathamrongsin S, et al.
High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol. 2009; 27(2–
3):153–60. PMID: 19839502.
33. Tanimoto T, Nguyen HC, Ishizaki A, Chung PT, Hoang TT, Nguyen VT, et al. Multiple routes of hepatitis
C virus transmission among injection drug users in Hai Phong, Northern Vietnam. Journal of medical
virology. 2010; 82(8):1355–63. PMID: 20572071. doi: 10.1002/jmv.21787
34. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography
for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy.
Journal of hepatology. 2011; 54(4):650–9. doi: 10.1016/j.jhep.2010.07.033 PMID: 21146892.
35. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis
and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune
Defic Syndr. 2006; 41(2):175–9. PMID: 16394849.
36. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C
virus infection. Journal of hepatology. 2014; 60(2):392–420. doi: 10.1016/j.jhep.2013.11.003 PMID:
24331294.
37. Obach D, Yazdanpanah Y, Esmat G, Avihingsanon A, Dewedar S, Durier N, et al. How to optimize
HCV treatment impact on life years saved in resource-constrained countries. Hepatology. 2015. doi:
10.1002/hep.27691 PMID: 25581111.
38. Bruggmann P, Falcato L, Dober S, Helbling B, Keiser O, Negro F, et al. Active intravenous drug use
during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent
patients. Journal of viral hepatitis. 2008; 15(10):747–52. doi: 10.1111/j.1365-2893.2008.01010.x PMID:
18637072.
39. Schulte B, Schutt S, Brack J, Isernhagen K, Deibler P, Dilg C, et al. Successful treatment of chronic
hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug and
alcohol dependence. 2010; 109(1–3):248–51. doi: 10.1016/j.drugalcdep.2010.01.009 PMID:
20167441.
40. Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, et al. HCV treatment rates and sustained
viral response among people who inject drugs in seven UK sites: real world results and modelling of
treatment impact. Journal of viral hepatitis. 2015; 22(4):399–408. doi: 10.1111/jvh.12338 PMID:
25288193; PubMed Central PMCID: PMC4409099.
HIV-HCV Coinfection in Vietnam
PLOSONE | DOI:10.1371/journal.pone.0153744 May 5, 2016 12 / 13
41. Hellard ME, Jenkinson R, Higgs P, Stoove MA, Sacks-Davis R, Gold J, et al. Modelling antiviral treat-
ment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. The Medical
journal of Australia. 2012; 196(10):638–41. PMID: 22676879.
42. Huu Bich T, Thi Quynh Nga P, Ngoc Quang L, Van Minh H, Ng N, Juvekar S, et al. Patterns of alcohol
consumption in diverse rural populations in the Asian region. Global health action. 2009;2. doi: 10.
3402/gha.v2i0.2017 PMID: 20027253; PubMed Central PMCID: PMC2785538.
43. Wang JH, Changchien CS, Hung CH, Eng HL, TungWC, Kee KM, et al. FibroScan and ultrasonogra-
phy in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. Journal of gastroenterol-
ogy. 2009; 44(5):439–46. Epub 2009/03/25. doi: 10.1007/s00535-009-0017-y PMID: 19308312.
44. World Health Organization, Global Hepatitis Programme, Global partners. http://www.who.int/hiv/
mediacentre/news/hep_calltoaction_new.pdf Last accessed 10 July 2015. 2014.
45. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver international: official journal
of the International Association for the Study of the Liver. 2013; 33 Suppl 1:68–79. Epub 2013/01/11.
doi: 10.1111/liv.12063 PMID: 23286849.
HIV-HCV Coinfection in Vietnam
PLOSONE | DOI:10.1371/journal.pone.0153744 May 5, 2016 13 / 13
